The PCCTC
@thepcctc.bsky.social
The Prostate Cancer Clinical Trials Consortium (PCCTC) translates scientific discoveries to improved standards of care. Visit pcctc.org to learn more.
The PCCTC's phase 2 study of talazoparib with or without enzalutamide in patients With metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate (TALENT) is now actively enrolling. To learn more visit clinicaltrials.gov/study/NCT068...
October 24, 2025 at 12:24 PM
The PCCTC's phase 2 study of talazoparib with or without enzalutamide in patients With metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate (TALENT) is now actively enrolling. To learn more visit clinicaltrials.gov/study/NCT068...
Learn more about the PCCTC-managed PROMISE, a registry of prostate cancer patients participating in a research study to learn how genetic differences can affect patient outcomes: www.prostatecancerpromise.org
July 18, 2025 at 4:30 PM
Learn more about the PCCTC-managed PROMISE, a registry of prostate cancer patients participating in a research study to learn how genetic differences can affect patient outcomes: www.prostatecancerpromise.org
PCCTC study of a novel CTLA-engaging IO plus Lu177-PSA-617 therapy in patients with metastatic castration-resistant #prostatecancer (mCRPC) at #ASCO25 #MedIQASCO25 with @tiansterzhangmd.bsky.social. Clear activity and safe!
June 3, 2025 at 1:30 PM
PCCTC study of a novel CTLA-engaging IO plus Lu177-PSA-617 therapy in patients with metastatic castration-resistant #prostatecancer (mCRPC) at #ASCO25 #MedIQASCO25 with @tiansterzhangmd.bsky.social. Clear activity and safe!
Join us tomorrow (Tuesday) at #ASCO25 as PCCTC investigators present at the prostate cancer oral abstract session (Hall D1 and Live Stream)!
June 2, 2025 at 4:11 PM
Join us tomorrow (Tuesday) at #ASCO25 as PCCTC investigators present at the prostate cancer oral abstract session (Hall D1 and Live Stream)!
Today at #ASCO25, Rapid Oral Sessions featuring PCCTC #prostatecancer science: the phase 2 Metacure trial, the novel B7H3 ADC DB‑1311/BNT324, and the phase 1 study results of JNJ-78278343
June 1, 2025 at 1:04 PM
Today at #ASCO25, Rapid Oral Sessions featuring PCCTC #prostatecancer science: the phase 2 Metacure trial, the novel B7H3 ADC DB‑1311/BNT324, and the phase 1 study results of JNJ-78278343
#ASCO25 is just days away. Be sure to check out the innovative PCCTC prostate cancer clinical research presented at this year's annual meeting in Chicago!
May 28, 2025 at 6:38 PM
#ASCO25 is just days away. Be sure to check out the innovative PCCTC prostate cancer clinical research presented at this year's annual meeting in Chicago!
We are excited to announce science from innovative PCCTC multi-center prostate cancer studies will be represented by 16 abstracts at #ASCO25!
May 22, 2025 at 9:05 PM
We are excited to announce science from innovative PCCTC multi-center prostate cancer studies will be represented by 16 abstracts at #ASCO25!
Just published: PCCTC study of Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer by Dr Karen A Autio and colleagues: pmc.ncbi.nlm.nih.gov/articles/PMC...
May 2, 2025 at 6:06 PM
Just published: PCCTC study of Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer by Dr Karen A Autio and colleagues: pmc.ncbi.nlm.nih.gov/articles/PMC...
Just Published: PCCTC leadership and colleagues release recommended clinical context and patient context data elements for liquid biopsy data submitted to data repositories and data commons (Clin Transl Sci): pmc.ncbi.nlm.nih.gov/articles/PMC...
May 1, 2025 at 1:03 PM
Just Published: PCCTC leadership and colleagues release recommended clinical context and patient context data elements for liquid biopsy data submitted to data repositories and data commons (Clin Transl Sci): pmc.ncbi.nlm.nih.gov/articles/PMC...
Congratulations, Howard I. Scher, MD, recipient of the Urology Care Foundation's Richard D. Williams, MD Prostate Cancer Research Excellence Award!
April 25, 2025 at 1:39 PM
Congratulations, Howard I. Scher, MD, recipient of the Urology Care Foundation's Richard D. Williams, MD Prostate Cancer Research Excellence Award!
#AACR25: Two proffered abstracts detailing the PCCTC-managed International Registry for Men With Advanced Prostate Cancer (IRONMAN) are featured at this year's AACR Annual Meeting www.aacr.org/meeting/aacr...
April 25, 2025 at 12:57 PM
#AACR25: Two proffered abstracts detailing the PCCTC-managed International Registry for Men With Advanced Prostate Cancer (IRONMAN) are featured at this year's AACR Annual Meeting www.aacr.org/meeting/aacr...
Cancer Centers Survivorship Research Forum 2025: Join our colleagues at Dana-Farber Cancer Center for two impactful days of connection, collaboration, and cutting-edge insights in survivorship research! www.eventbrite.com/e/cancer-cen...
April 24, 2025 at 6:54 PM
Cancer Centers Survivorship Research Forum 2025: Join our colleagues at Dana-Farber Cancer Center for two impactful days of connection, collaboration, and cutting-edge insights in survivorship research! www.eventbrite.com/e/cancer-cen...
Relationship Between Undetectable PSA Nadir and Outcomes for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in the PCCTC-managed International Registry for Men with Advanced Prostate Cancer (IRONMAN), via UroToday: www.urotoday.com/conference-h...
April 14, 2025 at 1:14 PM
Relationship Between Undetectable PSA Nadir and Outcomes for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in the PCCTC-managed International Registry for Men with Advanced Prostate Cancer (IRONMAN), via UroToday: www.urotoday.com/conference-h...
PCCTC investigators publish encouraging results from their phase 1 study of FOR46, a fully human antibody conjugated to monomethyl auristatin E, in metastatic castration-resistant prostate cancer: ascopubs.org/doi/pdfdirec...
April 3, 2025 at 12:22 PM
PCCTC investigators publish encouraging results from their phase 1 study of FOR46, a fully human antibody conjugated to monomethyl auristatin E, in metastatic castration-resistant prostate cancer: ascopubs.org/doi/pdfdirec...
PCCTC investigators and colleagues identify factors associated with successful genetic testing of bone tissue for patients with metastatic prostate cancer (Eur Urol Oncol. 2025 Apr;8(2):355-363): www.sciencedirect.com/science/arti...
April 1, 2025 at 2:08 PM
PCCTC investigators and colleagues identify factors associated with successful genetic testing of bone tissue for patients with metastatic prostate cancer (Eur Urol Oncol. 2025 Apr;8(2):355-363): www.sciencedirect.com/science/arti...
BREAKING: A vote is scheduled for today on a CR extension bill that includes a 57% cut to the Congressionally Directed Medical Research Programs, undermining progress in developing new treatments and improving patient outcomes. Contact your elected officials: zerocancer.quorum.us/campaign/SAV...
March 11, 2025 at 2:36 PM
BREAKING: A vote is scheduled for today on a CR extension bill that includes a 57% cut to the Congressionally Directed Medical Research Programs, undermining progress in developing new treatments and improving patient outcomes. Contact your elected officials: zerocancer.quorum.us/campaign/SAV...
CALL TO ACTION. Contact your elected officials and urge them to vote NO on a continuing resolution that includes a 57% cut to the Congressionally Directed Medical Research Program and its long-standing Prostate Cancer Research Program: zerocancer.quorum.us/campaign/SAV...
March 10, 2025 at 12:54 PM
CALL TO ACTION. Contact your elected officials and urge them to vote NO on a continuing resolution that includes a 57% cut to the Congressionally Directed Medical Research Program and its long-standing Prostate Cancer Research Program: zerocancer.quorum.us/campaign/SAV...
We are pleased to announce that science from seven Prostate Cancer Clinical Trials Consortium (PCCTC) studies will be presented at the 2025 ASCO Genitourinary Cancers Symposium later this week.
February 10, 2025 at 12:28 PM
We are pleased to announce that science from seven Prostate Cancer Clinical Trials Consortium (PCCTC) studies will be presented at the 2025 ASCO Genitourinary Cancers Symposium later this week.
Urology Practice publishes PHEN's peer-reviewed study co-authored by PCCTC CEO Jake Vinson: Black Men Not Being Asked to Participate in Prostate Cancer Clinical Trials www.auajournals.org/doi/epdf/10....
January 27, 2025 at 8:22 PM
Urology Practice publishes PHEN's peer-reviewed study co-authored by PCCTC CEO Jake Vinson: Black Men Not Being Asked to Participate in Prostate Cancer Clinical Trials www.auajournals.org/doi/epdf/10....
The PCCTC’s work as a clinical study consortium and contract research organization (CRO) is led by our Guiding Principles www.pcctc.org/guidingprinc...
January 22, 2025 at 3:06 PM
The PCCTC’s work as a clinical study consortium and contract research organization (CRO) is led by our Guiding Principles www.pcctc.org/guidingprinc...
Participating in the PCCTC-managed PROMISE Registry will add to our understanding of how genetic differences can affect patient outcomes, help family members understand their own risk of cancer, and guide discovery of new personalized treatments. To learn more visit www.prostatecancerpromise.org
January 14, 2025 at 4:53 PM
Participating in the PCCTC-managed PROMISE Registry will add to our understanding of how genetic differences can affect patient outcomes, help family members understand their own risk of cancer, and guide discovery of new personalized treatments. To learn more visit www.prostatecancerpromise.org
PCCTC investigators and colleagues collaborate on Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer (JCO Oncol Pract) pubmed.ncbi.nlm.nih.gov/39700441/
December 23, 2024 at 6:21 PM
PCCTC investigators and colleagues collaborate on Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer (JCO Oncol Pract) pubmed.ncbi.nlm.nih.gov/39700441/
DORA (NCT03574571) is the PCCTC-managed phase 3 trial of docetaxel vs. docetaxel and radium-223 for metastatic castration-resistant prostate cancer now accruing at 71 sites across the globe clinicaltrials.gov/study/NCT035...
December 3, 2024 at 7:57 PM
DORA (NCT03574571) is the PCCTC-managed phase 3 trial of docetaxel vs. docetaxel and radium-223 for metastatic castration-resistant prostate cancer now accruing at 71 sites across the globe clinicaltrials.gov/study/NCT035...
New webinar now available! The PCCTC, The Oncology Institute, and Trial Library recently partnered for insightful conversation titled “Decentralized Community-Engaged Recruitment to a Prostate Cancer Registry Study: docs.google.com/forms/d/e/1F...
November 25, 2024 at 1:22 PM
New webinar now available! The PCCTC, The Oncology Institute, and Trial Library recently partnered for insightful conversation titled “Decentralized Community-Engaged Recruitment to a Prostate Cancer Registry Study: docs.google.com/forms/d/e/1F...
Dear Colleagues, the Prostate Cancer Clinical Trials Consortium (PCCTC) is now on BlueSky. We invite you to follow us at
@thepcctc.bsky.social
Thank you for supporting our mission!
@thepcctc.bsky.social
Thank you for supporting our mission!
November 20, 2024 at 8:02 PM
Dear Colleagues, the Prostate Cancer Clinical Trials Consortium (PCCTC) is now on BlueSky. We invite you to follow us at
@thepcctc.bsky.social
Thank you for supporting our mission!
@thepcctc.bsky.social
Thank you for supporting our mission!